References
- Kooij SJ, Bejerot S, Blackwell A et al. European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry 10, 67 (2010).
- Rösler M, Casas M, Konofal E, Buitelaar J. Attention deficit hyperactivity disorder in adults. World J. Biol. Psychiatry 11(5), 684–698 (2010).
- Eme RF. Attention-deficit/hyperactivity disorder and correctional health care. J. Correct. Health Care 15(1), 5–18 (2009).
- von Polier GG, Vloet TD, Herpertz-Dahlmann B. ADHD and delinquency – a developmental perspective. Behav. Sci. Law 30(2), 121–139 (2012).
- Young S, Thome J. ADHD and offenders. World J. Biol. Psychiatry 12(Suppl. 1), 124–128 (2011).
- Young S, Goodwin E. Attention-deficit/hyperactivity disorder in persistent criminal offenders: the need for specialist treatment programs. Expert Rev. Neurother. 10(10), 1497–1500 (2010).
- Hanwella R, Senanayake M, de Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry 11, 176 (2011).
- Wilens TE, Morrison NR, Prince J. An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Expert Rev. Neurother. 11(10), 1443–1465 (2011).
- Lichtenstein P, Halldner L, Zetterqvist J et al. Medication for attention deficit–hyperactivity disorder and criminality. N. Engl. J. Med. 367(21), 2006–2014 (2012).
- Ginsberg Y, Hirvikoski T, Lindefors N. Attention deficit hyperactivity disorder (ADHD) among longer-term prison inmates is a prevalent, persistent and disabling disorder. BMC Psychiatry 10, 112 (2010).
- Ginsberg Y, Lindefors N. Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension. Br. J. Psychiatry 200(1), 68–73 (2012).
- Ginsberg Y, Hirvikoski T, Grann M, Lindefors N. Long-term functional outcome in adult prison inmates with ADHD receiving OROS-methylphenidate. Eur. Arch. Psychiatry Clin. Neurosci. 262(8), 705–724 (2012).
- Bogle KE, Smith BH. Illcit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences. Curr. Drug Abuse Rev. 2(2), 157–176 (2009).
- Wilens TE, Adler LA, Adams J et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J. Am. Acad. Child Adolesc. Psychiatry 47(1), 21–31 (2008).
- Spencer TJ, Biederman J, Ciccone PE et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am. J. Psychiatry 163(3), 387–395 (2006).
- Charach A, Yeung E, Climans T, Lillie E. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. J. Am. Acad. Child Adolesc. Psychiatry 50(1), 9–21 (2011).
- Biederman J, Monuteaux MC, Spencer T, Wilens TE, Macpherson HA, Faraone SV. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am. J. Psychiatry 165(5), 597–603 (2008).
- McCarthy S, Asherson P, Coghill D et al. Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br. J. Psychiatry 194(3), 273–277 (2009).
- Young S, Murphy CM, Coghill D. Avoiding the ‘twilight zone’: recommendations for the transition of services from adolescence to adulthood for young people with ADHD. BMC Psychiatry 11, 174 (2011).
Website
- National Institute for Health & Clinical Excellence (NICE). Attention Deficit Hyperactivity Disorder. Diagnosis and Management of ADHD in Children, Young People and Adults. The British Psychological Society and The Royal College of Psychiatrists (2009). www.nice.org.uk